the thriller round Eli Lilly’s weight problems drug

Elaine’s tales discover the increase in new weight problems remedies, new drug cost fashions, the methods firms are affected by FDA modifications, and the rising psychedelics drug sector. She co-writes The Readout e-newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You’ll be able to attain Elaine on Sign at elaineywchen.70.

Who obtained unique entry to Eli Lilly’s extremely anticipated weight problems candidate? Why are drugmakers spending a lot cash on acquisitions? And are hair loss medicine a superb funding?

We focus on all that and extra on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We deliver on our colleague Lizzy Lawrence to debate her scoop that Lilly and the Meals and Drug Administration have allowed one particular person to obtain the pharma firm’s weight problems candidate, retatrutide, by the FDA’s “compassionate use” program.

We additionally focus on the resurgence of M&A, Lilly’s curiosity in a hair loss drug, after which the FDA’s reversal on uncommon illness medicine.

For extra on Lilly granting entry of its drug to 1 particular person, go right here; to learn extra on M&A, go right here; to be taught extra in regards to the hair loss drug, go right here; and for extra on the FDA’s reversals, go right here and right here.

Make certain to enroll in “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.